HCV Approved Therapies - Hepatitis - Clinical Care Options

Highlights From EASL: HCV Approved Therapies

In this downloadable slideset, Jordan J. Feld, MD, MPH; Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD; and Stefan Zeuzem, MD, review key studies on currently approved HCV therapies presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 5/11/2015
OPTIMIST-1: Simeprevir + Sofosbuvir for 12 Weeks Highly Effective for Treatment of GT1 HCV Treatment–Naive and Treatment–Experienced Patients Without Cirrhosis

While the 12-week regimen was effective regardless of HCV genotype 1 subtype or presence of Q80K mutation, efficacy was diminished when treatment was shortened to 8 weeks.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 4/30/2015
RUBY-1: 12 Weeks of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin Well Tolerated in Treatment-Naive, Noncirrhotic Patients With Genotype 1 HCV Infection and Stage 4/5 CKD

Early efficacy data from this small patient group, which included patients on hemodialysis, suggests treatment effective in subtype 1a and 1b populations.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 4/30/2015
OPTIMIST-2: 83% SVR12 With 12-Week Regimen of Simeprevir Plus Sofosbuvir in Patients With Genotype 1 HCV Infection and Compensated Cirrhosis

SVR12 rates were 88% in treatment-naive patients and 79% in treatment-experienced patients—higher than historical controls with earlier approved DAA plus peginterferon/ribavirin-based regimens.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 4/30/2015
Evaluation of On-Treatment HCV RNA Levels and Response to Modern HCV Therapies

In patients receiving a broad range of sofosbuvir-containing regimens, SVR rates higher in patients without detectable Week 4 HCV RNA vs with detectable Week 4 HCV RNA; further analysis required.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 4/29/2015
BOSON: Higher SVR12 Rates With 12 Weeks of Sofosbuvir Plus PegIFN/RBV vs 16-24 Weeks of Sofosbuvir Plus RBV in Genotype 2/3 HCV–Infected Patients

In patients with genotype 3 HCV infection, sofosbuvir plus pegIFN/RBV more effective than sofosbuvir plus RBV regimens regardless of treatment history or cirrhosis.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 4/28/2015
HCV-TARGET: Sofosbuvir-Based Therapy Being Adopted in Real-World Setting for Patients With Cirrhosis and MELD Scores Over 10

Among patients with genotype 1 HCV infection, sofosbuvir plus simeprevir was selected most commonly and associated with 74% SVR12.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 4/27/2015
High SVR12 Rates Following Ledipasvir/Sofosbuvir for 12 Weeks in Patients With Genotype 4 or 5 HCV Infection

Ledipasvir/sofosbuvir effective with very low rates of serious adverse events and no treatment-related discontinuations in patients with genotype 4 or 5 HCV infection.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 4/27/2015
ION-4: 96% SVR12 Rate With LDV/SOF for 12 Weeks in Patients Coinfected With HIV and Genotype 1 or 4 HCV

In multivariate analysis, black race only factor associated with treatment failure.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 4/26/2015
High Incidence of HCV Reinfection Following SVR Among Patients Who Relapse to Injection Drug Use

Incidence of HCV reinfection 4.7/100 person-years among patients who relapsed to injection drug use vs 1.8/100 person-years among those with any previous injection drug use.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 4/26/2015

Other Sites

Topics

Educational Formats

Program Resources

User Resources

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

HCV Approved Therapies Source: 2015 Annual Meeting of the European Association for the Study of the Liver*
Conference Program HCV Investigational Therapies • Capsule Summaries (12) • Downloadable slideset HCV Approved Therapies • Capsule Summaries (13) • Downloadable slideset Highlights from the Meeting • Highlights From EASL 2015 ClinicalThought • EASL 2015: HCV Resistance Testing • Treating GT3 HCV Infection	Latest Content 10 of 14 Shown Highlights From EASL: HCV Approved Therapies In this downloadable slideset, Jordan J. Feld, MD, MPH; Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD; and Stefan Zeuzem, MD, review key studies on currently approved HCV therapies presented at the 2015 Annual Meeting of the European Association for the Study of the Liver. Source: 2015 Annual Meeting of the European Association for the Study of the Liver Date Posted: 5/11/2015 OPTIMIST-1: Simeprevir + Sofosbuvir for 12 Weeks Highly Effective for Treatment of GT1 HCV Treatment–Naive and Treatment–Experienced Patients Without Cirrhosis While the 12-week regimen was effective regardless of HCV genotype 1 subtype or presence of Q80K mutation, efficacy was diminished when treatment was shortened to 8 weeks. Source: 2015 Annual Meeting of the European Association for the Study of the Liver Date Posted: 4/30/2015 RUBY-1: 12 Weeks of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin Well Tolerated in Treatment-Naive, Noncirrhotic Patients With Genotype 1 HCV Infection and Stage 4/5 CKD Early efficacy data from this small patient group, which included patients on hemodialysis, suggests treatment effective in subtype 1a and 1b populations. Source: 2015 Annual Meeting of the European Association for the Study of the Liver Date Posted: 4/30/2015 OPTIMIST-2: 83% SVR12 With 12-Week Regimen of Simeprevir Plus Sofosbuvir in Patients With Genotype 1 HCV Infection and Compensated Cirrhosis SVR12 rates were 88% in treatment-naive patients and 79% in treatment-experienced patients—higher than historical controls with earlier approved DAA plus peginterferon/ribavirin-based regimens. Source: 2015 Annual Meeting of the European Association for the Study of the Liver Date Posted: 4/30/2015 Evaluation of On-Treatment HCV RNA Levels and Response to Modern HCV Therapies In patients receiving a broad range of sofosbuvir-containing regimens, SVR rates higher in patients without detectable Week 4 HCV RNA vs with detectable Week 4 HCV RNA; further analysis required. Source: 2015 Annual Meeting of the European Association for the Study of the Liver Date Posted: 4/29/2015 BOSON: Higher SVR12 Rates With 12 Weeks of Sofosbuvir Plus PegIFN/RBV vs 16-24 Weeks of Sofosbuvir Plus RBV in Genotype 2/3 HCV–Infected Patients In patients with genotype 3 HCV infection, sofosbuvir plus pegIFN/RBV more effective than sofosbuvir plus RBV regimens regardless of treatment history or cirrhosis. Source: 2015 Annual Meeting of the European Association for the Study of the Liver Date Posted: 4/28/2015 HCV-TARGET: Sofosbuvir-Based Therapy Being Adopted in Real-World Setting for Patients With Cirrhosis and MELD Scores Over 10 Among patients with genotype 1 HCV infection, sofosbuvir plus simeprevir was selected most commonly and associated with 74% SVR12. Source: 2015 Annual Meeting of the European Association for the Study of the Liver Date Posted: 4/27/2015 High SVR12 Rates Following Ledipasvir/Sofosbuvir for 12 Weeks in Patients With Genotype 4 or 5 HCV Infection Ledipasvir/sofosbuvir effective with very low rates of serious adverse events and no treatment-related discontinuations in patients with genotype 4 or 5 HCV infection. Source: 2015 Annual Meeting of the European Association for the Study of the Liver Date Posted: 4/27/2015 ION-4: 96% SVR12 Rate With LDV/SOF for 12 Weeks in Patients Coinfected With HIV and Genotype 1 or 4 HCV In multivariate analysis, black race only factor associated with treatment failure. Source: 2015 Annual Meeting of the European Association for the Study of the Liver Date Posted: 4/26/2015 High Incidence of HCV Reinfection Following SVR Among Patients Who Relapse to Injection Drug Use Incidence of HCV reinfection 4.7/100 person-years among patients who relapsed to injection drug use vs 1.8/100 person-years among those with any previous injection drug use. Source: 2015 Annual Meeting of the European Association for the Study of the Liver Date Posted: 4/26/2015 10 of 14 Shown Show 4 More Loading...	Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC Contact Info Educational grants provided by: Educational grants support only the CME-certified components of this program.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Source: 2015 Annual Meeting of the European Association for the Study of the Liver*

Conference Program

Latest Content